{"hands_on_practices": [{"introduction": "Understanding Autosomal Dominant Polycystic Kidney Disease (ADPKD) begins at the cellular level with the \"second-hit\" hypothesis. This model explains why, despite a germline mutation in every cell, cysts form as focal, sporadic events. This exercise applies fundamental principles of probability to quantify the risk of a cyst-initiating \"second hit\" within a single cell lineage, providing a tangible grasp of how a low-probability molecular event, when scaled across millions of tubules, results in a high-penetrance clinical disease [@problem_id:4801047].", "problem": "A patient with Autosomal Dominant Polycystic Kidney Disease (ADPKD) carries a germline heterozygous variant in the polycystin-1 gene ($\\mathrm{PKD1}$). In the somatic second-hit model of cyst initiation, a focal tubular epithelial cell can initiate a cyst when a subsequent somatic event (e.g., a mutation or loss of heterozygosity (LOH)) functionally inactivates the remaining wild-type allele. Consider a single tubular epithelial cell lineage that undergoes $N=10^{6}$ mitotic divisions over time. Suppose the per-division probability of a somatic second hit that inactivates the wild-type allele is $\\mu=1\\times 10^{-7}$, and assume independence of divisions with a constant per-division risk across the lineage.\n\nUsing first principles of probability for independent Bernoulli trials, derive from the complement rule the probability $P$ that at least one effective second hit occurs somewhere in this lineage. Then evaluate $P$ numerically for the given $\\mu$ and $N$. Express your answer as a decimal fraction and round to four significant figures. Finally, explain conceptually (not as part of the numerical answer) how this focal probability relates to mosaic cyst initiation in the context of a germline heterozygous $\\mathrm{PKD1}$ variant.", "solution": "The problem statement has been critically validated and is deemed valid. It is scientifically grounded in the accepted two-hit model of cystogenesis in Autosomal Dominant Polycystic Kidney Disease (ADPKD), well-posed with all necessary information provided, and objective in its formulation. The problem asks for the derivation and calculation of a probability based on a series of independent Bernoulli trials and a conceptual explanation of the result in a biological context.\n\nThe problem can be modeled as a sequence of $N$ independent Bernoulli trials, where each trial corresponds to a single mitotic division of a cell in the lineage. A \"success\" is defined as the occurrence of a somatic second hit that inactivates the wild-type $\\mathrm{PKD1}$ allele. The probability of success in any single trial is given as $\\mu$.\n\nLet $S_i$ be the event of a second hit occurring during the $i$-th division, for $i = 1, 2, \\dots, N$.\nThe probability of this event is $P(S_i) = \\mu$.\nThe event that no second hit occurs during the $i$-th division is the complement event, denoted $S_i^c$. Its probability is $P(S_i^c) = 1 - \\mu$.\n\nThe problem asks for the probability $P$ that at least one effective second hit occurs somewhere in the lineage of $N$ divisions. This can be expressed as the probability of the union of all success events:\n$$P = P(S_1 \\cup S_2 \\cup \\dots \\cup S_N)$$\nCalculating this directly is cumbersome. It is more straightforward to use the complement rule, as requested by the problem. The complement of \"at least one hit\" is \"zero hits\".\nLet $A$ be the event that at least one hit occurs in $N$ divisions. The complement event, $A^c$, is that no hits occur in any of the $N$ divisions.\n$$P(A) = 1 - P(A^c)$$\nThe event $A^c$ corresponds to the intersection of the events where no hit occurred in each individual division:\n$$A^c = S_1^c \\cap S_2^c \\cap \\dots \\cap S_N^c$$\nSince the divisions are assumed to be independent events, the probability of the intersection is the product of the individual probabilities:\n$$P(A^c) = P(S_1^c) \\times P(S_2^c) \\times \\dots \\times P(S_N^c) = \\prod_{i=1}^{N} P(S_i^c)$$\nSince $P(S_i^c) = 1 - \\mu$ for all $i$, this simplifies to:\n$$P(A^c) = (1 - \\mu)^N$$\nSubstituting this back into the complement rule, we obtain the desired expression for $P$:\n$$P = 1 - (1 - \\mu)^N$$\nThis is the derived probability that at least one effective second hit occurs in the lineage.\n\nNow, we evaluate $P$ numerically using the given values:\nNumber of divisions, $N = 10^6$.\nPer-division probability of a second hit, $\\mu = 1 \\times 10^{-7}$.\n\nSubstituting these values into the derived formula:\n$$P = 1 - (1 - 1 \\times 10^{-7})^{10^6}$$\n$$P = 1 - (1 - 0.0000001)^{1000000}$$\n$$P = 1 - (0.9999999)^{1000000}$$\nCalculating the value of the term $(0.9999999)^{1000000}$:\n$$(0.9999999)^{1000000} \\approx 0.90483736$$\nTherefore, the probability $P$ is:\n$$P \\approx 1 - 0.90483736 = 0.09516264$$\nThe problem requires the answer to be rounded to four significant figures. The first four significant figures are $9$, $5$, $1$, and $6$. The fifth significant figure is $2$, which is less than $5$, so we do not round up.\n$$P \\approx 0.09516$$\n\nConceptually, this probability $P \\approx 0.09516$ (or about $9.5\\%$) represents the risk that a *single* tubular epithelial cell lineage, starting from a cell with a germline $\\mathrm{PKD1}$ mutation, will give rise to a cyst-initiating cell over the course of $10^6$ divisions. This risk for a single lineage is relatively low.\n\nHowever, the human kidney is composed of millions of renal tubules, each containing thousands of such epithelial cells. Each of these cells can be considered the progenitor of a distinct lineage, running an independent \"probabilistic experiment\". If there are, for example, $M$ such independent lineages in the kidneys, the probability that *at least one* of them initiates a cyst is $1 - (1-P)^M$. Given that $M$ is a very large number, this probability approaches $1$ (certainty), even though $P$ itself is small. This explains the high penetrance of the disease—why individuals with a germline $\\mathrm{PKD1}$ mutation almost invariably develop numerous cysts. The cysts arise from focal, sporadic second-hit events, meaning the kidney tissue becomes a \"mosaic\" of a vast majority of cells that are heterozygous at the $\\mathrm{PKD1}$ locus (one hit) and a small number of clonal cell populations that are functionally null for $\\mathrm{PKD1}$ (two hits) and which go on to form the cysts. This calculated focal probability is the fundamental unit of risk that, when scaled up to the level of the entire organ, accounts for the clinical phenotype of ADPKD.", "answer": "$$\\boxed{0.09516}$$", "id": "4801047"}, {"introduction": "The macroscopic consequence of cyst initiation and growth is the progressive enlargement of the kidneys. Total Kidney Volume (TKV) has emerged as a crucial biomarker for tracking disease progression, and its rate of change is a key endpoint in clinical trials. This practice problem introduces a quantitative model of TKV growth, allowing you to derive a patient-specific growth rate from serial imaging data, a core skill for objectively monitoring disease activity and stratifying progression risk [@problem_id:4800872].", "problem": "A $42$-year-old adult with Autosomal Dominant Polycystic Kidney Disease (ADPKD) is followed longitudinally with serial imaging of Total Kidney Volume (TKV). TKV is considered a validated surrogate biomarker of disease progression in ADPKD when measured reproducibly and adjusted for body size. Height-adjusted Total Kidney Volume (htTKV) is defined as the ratio of total kidney volume to patient height. Assume the trajectory of TKV over time $t$ (in years) follows continuous exponential growth such that the instantaneous rate of change of volume is proportional to the current volume, consistent with cyst burden expansion under relatively stable physiological conditions. The measured TKV increases from $900$ mL at baseline ($t=0$) to $1080$ mL at $t=2$ years, and the patient’s height is $1.70$ m.\n\nStarting from the definition that the instantaneous growth rate is proportional to the current volume, derive the continuous growth parameter $r$ (in per year) that characterizes this trajectory between the two time points. Then compute the height-adjusted total kidney volume at baseline and at $t=2$ years. Express $r$ as a decimal per year and each htTKV in $\\text{mL/m}$.\n\nRound all reported quantities to four significant figures. Provide the final answer in the order: $r$, baseline htTKV, $2$-year htTKV.", "solution": "The problem statement is deemed valid. It is scientifically grounded, well-posed, and objective. The provided clinical context, model, and data are consistent and sufficient for deriving a unique solution.\n\nThe problem states that the instantaneous rate of change of Total Kidney Volume (TKV), denoted by $V(t)$, is proportional to the current volume. This is the definition of continuous exponential growth, which can be expressed as the following first-order linear ordinary differential equation:\n$$\n\\frac{dV}{dt} = rV\n$$\nwhere $r$ is the continuous growth parameter in units of per year.\n\nThis differential equation can be solved by separation of variables:\n$$\n\\frac{dV}{V} = r \\, dt\n$$\nIntegrating both sides gives:\n$$\n\\int \\frac{1}{V} \\, dV = \\int r \\, dt\n$$\n$$\n\\ln|V| = rt + C\n$$\nwhere $C$ is the constant of integration. We can solve for $V$ by exponentiating both sides:\n$$\n|V| = \\exp(rt + C) = \\exp(C) \\exp(rt)\n$$\nSince volume $V$ must be positive, we can drop the absolute value. We define a new constant $V_0 = \\exp(C)$, which represents the initial volume at time $t=0$. The solution to the differential equation is the standard exponential growth model:\n$$\nV(t) = V_0 \\exp(rt)\n$$\n\nThe problem provides the following data:\n-   The baseline TKV at $t=0$ is $V(0) = 900 \\text{ mL}$. This directly gives us the value of $V_0$. So, $V_0 = 900 \\text{ mL}$.\n-   The TKV at $t=2$ years is $V(2) = 1080 \\text{ mL}$.\n\nWe can now write the specific model for this patient's TKV growth:\n$$\nV(t) = 900 \\exp(rt)\n$$\nTo find the growth parameter $r$, we substitute the second data point, $V(2) = 1080 \\text{ mL}$, into the equation:\n$$\n1080 = 900 \\exp(r \\cdot 2)\n$$\nFirst, we isolate the exponential term by dividing both sides by $900$:\n$$\n\\frac{1080}{900} = \\exp(2r)\n$$\n$$\n1.2 = \\exp(2r)\n$$\nNext, we take the natural logarithm of both sides to solve for the exponent:\n$$\n\\ln(1.2) = 2r\n$$\nFinally, we solve for $r$:\n$$\nr = \\frac{\\ln(1.2)}{2}\n$$\nNow, we compute the numerical value and round to four significant figures.\n$$\nr \\approx \\frac{0.18232155679}{2} \\approx 0.09116077839 \\text{ year}^{-1}\n$$\nRounding to four significant figures, we get:\n$$\nr \\approx 0.09116 \\text{ year}^{-1}\n$$\n\nNext, we are asked to compute the height-adjusted total kidney volume (htTKV) at baseline ($t=0$) and at $t=2$ years. The patient's height is given as $h = 1.70 \\text{ m}$. The definition of htTKV is:\n$$\n\\text{htTKV} = \\frac{\\text{TKV}}{h}\n$$\n\nThe baseline htTKV is calculated using $V(0) = 900 \\text{ mL}$:\n$$\n\\text{htTKV}(0) = \\frac{V(0)}{h} = \\frac{900 \\text{ mL}}{1.70 \\text{ m}} \\approx 529.41176 \\text{ mL/m}\n$$\nRounding to four significant figures, we get:\n$$\n\\text{htTKV}(0) \\approx 529.4 \\text{ mL/m}\n$$\n\nThe htTKV at $t=2$ years is calculated using $V(2) = 1080 \\text{ mL}$:\n$$\n\\text{htTKV}(2) = \\frac{V(2)}{h} = \\frac{1080 \\text{ mL}}{1.70 \\text{ m}} \\approx 635.29411 \\text{ mL/m}\n$$\nRounding to four significant figures, we get:\n$$\n\\text{htTKV}(2) \\approx 635.3 \\text{ mL/m}\n$$\n\nThe three requested quantities, rounded to four significant figures, are:\n1.  Growth parameter $r$: $0.09116$\n2.  Baseline htTKV: $529.4$\n3.  $2$-year htTKV: $635.3$", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.09116  529.4  635.3\n\\end{pmatrix}\n}\n$$", "id": "4800872"}, {"introduction": "Clinical management in ADPKD is challenged by the disease's significant variability in progression. To address this, validated risk stratification tools are essential for personalizing care and guiding long-term strategy. This exercise provides hands-on practice with the Predicting Renal Outcome in Polycystic Kidney Disease (PROPKD) score, demonstrating how to integrate genetic data with key clinical milestones to generate a robust prognostic estimate and classify a patient's risk of progression to kidney failure [@problem_id:4800933].", "problem": "A clinician seeks to estimate disease progression severity in Autosomal Dominant Polycystic Kidney Disease (ADPKD) using the Predicting Renal Outcome in Polycystic Kidney Disease (PROPKD) point-based risk model. The model integrates biologically grounded determinants of cystic disease severity, each reflecting an increased hazard for accelerated decline in kidney function: sex-related modifiers, early-onset hypertension (a proxy for early intrarenal cystic burden and endothelial dysfunction), early-onset urologic events (a proxy for cyst rupture/bleeding or infection due to higher cyst burden), and genotype severity ranking based on the gene involved (*PKD1* versus *PKD2*) and its mutation class (truncating versus non-truncating).\n\nUse the following well-tested facts that define the PROPKD additive point system:\n- Male sex contributes $1$ point.\n- First diagnosis of hypertension before age $35$ years contributes $2$ points.\n- First urologic event before age $35$ years (including gross hematuria, cyst infection, or flank pain requiring medical evaluation) contributes $2$ points.\n- Genotype contributes $4$ points for a PKD1 truncating variant, $2$ points for a PKD1 non-truncating variant, and $0$ points for a PKD2 variant or no detectable mutation.\n\nA male patient had his first documented hypertension at age $32$ years, first episode of gross hematuria at age $29$ years, and genetic testing identified a PKD1 truncating variant. Compute the total PROPKD score and assign the risk category according to the following mapping derived from the distribution of total points and their association with earlier end-stage kidney disease:\n- Low risk: total score in $[0,3]$.\n- Intermediate risk: total score in $[4,6]$.\n- High risk: total score in $[7,9]$.\n\nFor the final output, encode the risk category as a numeric code $c$ where low risk $\\to c=0$, intermediate risk $\\to c=1$, and high risk $\\to c=2$. Express your final answer as a two-entry row matrix containing the total PROPKD score and the category code. No rounding is required. The final answer must be unitless.", "solution": "The problem is valid. It is scientifically grounded in established clinical risk modeling for Autosomal Dominant Polycystic Kidney Disease (ADPKD), specifically the PROPKD score. The problem is well-posed, with all necessary data and unambiguous rules provided, ensuring a unique and computable solution. The language is objective and the premises are factually consistent with the cited medical literature.\n\nThe task is to compute the total PROPKD score for a given patient and classify them into a risk category. The total score, which we will denote as $S_{total}$, is an additive combination of points derived from four factors: sex, age of hypertension onset, age of first urologic event, and genotype.\n\nLet $P_{sex}$ be the points for sex, $P_{htn}$ be the points for hypertension, $P_{uro}$ be the points for urologic events, and $P_{gen}$ be the points for genotype. The total score is given by the sum:\n$$ S_{total} = P_{sex} + P_{htn} + P_{uro} + P_{gen} $$\n\nWe will evaluate each component based on the patient's data and the provided rules.\n\n1.  **Points for Sex ($P_{sex}$):**\n    The patient is male. The rule states: \"Male sex contributes $1$ point.\"\n    Therefore, $P_{sex} = 1$.\n\n2.  **Points for Hypertension ($P_{htn}$):**\n    The patient's first diagnosis of hypertension was at age $32$ years. The rule is: \"First diagnosis of hypertension before age $35$ years contributes $2$ points.\"\n    Since the patient's age of onset, $32$, is less than the threshold age of $35$, this condition is satisfied.\n    Therefore, $P_{htn} = 2$.\n\n3.  **Points for Urologic Event ($P_{uro}$):**\n    The patient experienced his first episode of gross hematuria at age $29$ years. Gross hematuria is explicitly included as a qualifying urologic event. The rule is: \"First urologic event before age $35$ years...contributes $2$ points.\"\n    Since the patient's age at this event, $29$, is less than the threshold age of $35$, this condition is satisfied.\n    Therefore, $P_{uro} = 2$.\n\n4.  **Points for Genotype ($P_{gen}$):**\n    Genetic testing identified a PKD1 truncating variant. The rule is: \"Genotype contributes $4$ points for a PKD1 truncating variant.\"\n    Therefore, $P_{gen} = 4$.\n\nNow, we compute the total PROPKD score, $S_{total}$, by summing the points from each category:\n$$ S_{total} = P_{sex} + P_{htn} + P_{uro} + P_{gen} = 1 + 2 + 2 + 4 = 9 $$\nThe total PROPKD score for this patient is $9$.\n\nNext, we must assign the risk category based on the total score. The categories are defined as follows:\n- Low risk: total score in the interval $[0, 3]$.\n- Intermediate risk: total score in the interval $[4, 6]$.\n- High risk: total score in the interval $[7, 9]$.\n\nOur calculated score is $S_{total} = 9$. This value falls within the interval for the high-risk category, as $7 \\le 9 \\le 9$.\n\nFinally, we must encode this risk category as a numeric code, $c$, according to the provided mapping:\n- Low risk $\\to c=0$.\n- Intermediate risk $\\to c=1$.\n- High risk $\\to c=2$.\n\nSince the patient is in the high-risk category, the corresponding numeric code is $c = 2$.\n\nThe problem requires the final answer to be a two-entry row matrix containing the total PROPKD score and the category code. The two values are the score, $S_{total} = 9$, and the code, $c = 2$.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n9  2\n\\end{pmatrix}\n}\n$$", "id": "4800933"}]}